Figure 1.
Figure 1. HuMab VN18 inhibits platelet aggregation in platelet-rich plasma. (A) Addition of increasing amounts of huMab VN18 to platelet-rich plasma inhibited ADP-induced platelet aggregation dose dependently, whereas a control huMab (B) had no effect. 1 indicates no antibody; 2, 1 μg/mL; 3, 10 μg/mL; 4, 50 μg/mL.

HuMab VN18 inhibits platelet aggregation in platelet-rich plasma. (A) Addition of increasing amounts of huMab VN18 to platelet-rich plasma inhibited ADP-induced platelet aggregation dose dependently, whereas a control huMab (B) had no effect. 1 indicates no antibody; 2, 1 μg/mL; 3, 10 μg/mL; 4, 50 μg/mL.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal